Literature DB >> 7635501

Azithromycin and syphilis.

F J Bowden, B Farmer, J Bullen, V Chamberlain, I Bastian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7635501      PMCID： PMC1195500          DOI： 10.1136/sti.71.3.196-a

Source DB:  PubMed          Journal:  Genitourin Med        ISSN： 0266-4348


× No keyword cloud information.
  5 in total

1.  In-vitro activity of azithromycin and CP-63,956 against Treponema pallidum.

Authors:  L V Stamm; E A Parrish
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

2.  Efficacy of azithromycin for therapy of active syphilis in the rabbit model.

Authors:  S A Lukehart; M J Fohn; S A Baker-Zander
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women.

Authors:  M A Waugh
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

4.  A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group.

Authors:  D H Martin; T F Mroczkowski; Z A Dalu; J McCarty; R B Jones; S J Hopkins; R B Johnson
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

5.  Pilot study of azithromycin for treatment of primary and secondary syphilis.

Authors:  M S Verdon; H H Handsfield; R B Johnson
Journal:  Clin Infect Dis       Date:  1994-09       Impact factor: 9.079
  5 in total
  2 in total

1.  Pilot study of azithromycin in the treatment of genital donovanosis.

Authors:  F J Bowden; J Mein; C Plunkett; I Bastian
Journal:  Genitourin Med       Date:  1996-02

2.  Detection of azithromycin resistance in Treponema pallidum by real-time PCR.

Authors:  Mark W Pandori; Charmie Gordones; Lina Castro; Joseph Engelman; Mark Siedner; Sheila Lukehart; Jeffrey Klausner
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.